サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：自己免疫性肝炎診断・治療の世界市場：予測（2022年～2028年）
市場調査レポート
商品コード
1123337

自己免疫性肝炎診断・治療の世界市場：予測（2022年～2028年）

Global Autoimmune Hepatitis Diagnosis and Treatment Market Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 115 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
自己免疫性肝炎診断・治療の世界市場：予測（2022年～2028年）
出版日: 2022年08月05日
発行: Orion Market Research
ページ情報: 英文 115 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の自己免疫性肝炎診断・治療の市場規模は、予測期間（2022年～2028年）中に5.7%のCAGRで成長すると予想されています。肝臓関連疾患を検出するための高感度かつ迅速な検査法の開発に対して主要企業の取り組みが活発化していること、ライフスタイルの変化は、自己免疫性肝炎診断・治療市場の成長を促進しています。

当レポートでは、世界の自己免疫性肝炎診断・治療市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポート概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • 規則

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の自己免疫性肝炎診断・治療市場：診断別
    • 血液検査
    • 画像検査
    • 肝生検
  • 世界の自己免疫性肝炎診断・治療市場：治療別
    • 投薬
    • コルチコステロイド
    • 免疫系抑制剤
    • 肝移植
  • 世界の自己免疫性肝炎診断・治療市場：タイプ別
    • タイプⅠ
    • タイプⅡ
    • バリアント自己免疫性肝炎
  • 世界の自己免疫性肝炎診断・治療市場：エンドユーザー別
    • 病院とクリニック
    • 診断センター
    • 研究機関

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • AbbVie, Inc.
  • Arihantanam Life Care Pvt Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon, Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Co.
  • Cipla, Ltd.
  • GlaxoSmithKline PLC
  • Gilead Lifesciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Inova Diagnostics, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Organovo Holdings, Inc.
  • Pfizer, Inc.
  • Upcyte Technologies GmbH
図表

LIST OF TABLES

  • 1. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR BLOOD TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR LIVER BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 6. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR MEDICATION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 7. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR IMMUNE SYSTEM SUPPRESSORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT IN LIVER TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 11. GLOBAL TYPE-I AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL TYPE-II AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL VARIANT AIH AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENTMARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 15. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 17. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT FOR RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 18. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 24. EUROPEAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 25. EUROPEAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 26. EUROPEAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 27. EUROPEAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 28. EUROPEAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 30. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 34. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET, 2020-2027 (%)
  • 4. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 5. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 6. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 7. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY END-USER 2020 VS 2027 (%)
  • 8. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL BLOOD TEST FOR AUTOIMMUNE HEPATITIS DIAGNOSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL IMAGING TEST FOR AUTOIMMUNE HEPATITIS DIAGNOSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL LIVER BIOPSY FOR AUTOIMMUNE HEPATITIS DIAGNOSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL MEDICATION FOR AUTOIMMUNE HEPATITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL CORTICOSTEROIDS FOR AUTOIMMUNE HEPATITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL IMMUNE SYSTEM SUPPRESSORS FOR AUTOIMMUNE HEPATITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL LIVER TRANSPLANT FOR AUTOIMMUNE HEPATITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL TYPE-I AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL TYPE-II AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL VARIANT AIH AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT IN HOSPITALS AND CLINICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 20. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT IN DIAGNOSTIC CENTRE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 21. GLOBAL AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT IN RESEARCH INSTITUTIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 22. US AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 23. CANADA AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 24. UK AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 25. FRANCE AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 26. GERMANY AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 27. ITALY AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 28. SPAIN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 29. REST OF EUROPE AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 30. INDIA AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 31. CHINA AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 32. JAPAN AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 33. SOUTH KOREA AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 34. REST OF ASIA-PACIFIC AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 35. REST OF THE WORLD AUTOIMMUNE HEPATITIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027($ MILLION)
目次
Product Code: OMR2019499

Global Autoimmune Hepatitis Diagnosis and Treatment Market Size, Share & Trends Analysis Report By Diagnosis ( Blood Test, Imaging Test, Liver Biopsy) By Treatment ( Medication, Corticosteroids, Immune System Suppressors, Liver Transplant), By Type (Type-I, Type-II, Variant AIH) End-User (Hospitals & Clinics, Diagnostic Centre, and Research Institutions) Forecast Period 2021-2027

The global autoimmune hepatitis diagnosis and treatment market are anticipated to grow at a CAGR of around 5.7% during the forecast period. Autoimmune hepatitis is a long-lasting chronic disease that is caused when the immune system of the body arracks the normal cells and results in liver damage. The disease develops as a result of an inherited tendency or genetic predisposition, which increases the demand for autoimmune hepatitis medication. The factors attributing to the growth of the market include rising initiatives by major market players to develop highly sensitive and rapid tests to detect liver associated diseases and changing lifestyles where an increase in consumption of alcohol is causing severe liver diseases. However, The strict regulation for liver transplantation is a serious hindrance to the growth of the autoimmune hepatitis diagnosis and treatment market.

Impact of COVID-19 on Global Autoimmune Hepatitis Diagnosis and Treatment Market

A growing number of COVID-19 cases have been linked to Autoimmune Hepatitis and liver diseases. The reasons for liver injury during the COVID-19 can be attributed to different factors that include hypoxia, hepatic congestion, drug-induced liver diseases, and virus-induced systematic inflammation. The patients with cirrhosis, COVID-19 has been linked to hepatic decompensation and resulting liver-related mortality. However, COVID19's impact on healthcare resources had a negative impact on the delivery of care and the outcomes of patients with chronic liver disease. As a result, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease, which had a partial negative impact on the healthcare industry during the pandemic.

Segmental Outlook

The global autoimmune hepatitis diagnosis and treatment market are segmented based on diagnosis, treatment, types, and end-user. Based on the diagnosis, the market is segmented into blood tests, imaging tests, and liver biopsy. Based on treatment, the market is segmented into Medication, corticosteroids, immune system suppressors, liver transplants. Further, based on type the market is segregated into Type-I, Type-II, Variant AIH. Furthermore, on the basis of end-user, the market is classified into hospitals & clinics, diagnostic centers, and research institutions.

Global Autoimmune Hepatitis Diagnosis and Treatment Market Share by Diagnosis, 2020 (%)

Global Autoimmune Hepatitis Diagnosis and Treatment Market Share

The imaging test is projected to hold a significant share in the global Autoimmune Hepatitis Diagnosis and Treatment market

Among diagnosis, the imaging test segment is projected to have a significant share in the global market. This is due to an increase in the number of initiatives undertaken by key players in the market for liver disease diagnostics to develop advanced imaging techniques. Moreover, the factors such as the growing demand for early disease detection and the widening scope of clinical applications, as well as the rapidly growing geriatric population with such chronic disorders will be also attributing to the growth of the segment. An imaging test, includes X-ray, ultrasound, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and other methods.

Regional Outlooks

The global autoimmune hepatitis diagnosis and treatment market are further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Due to a high prevalence rate of urinary tract infections, North America is projected to have a significant share in the global market. Increased alcoholic beverage consumption, illegal drug intake, an increase in the prevalence of liver diseases, and rising government and private awareness programs have all contributed to the growth of the North American autoimmune hepatitis diagnosis and treatment market. However, stringent regulatory approvals for liver disease treatment drugs and vaccines, as well as resistance to antiviral drugs being used for hepatitis B and hepatitis C treatment, restrict the market to some extent.

Global Autoimmune Hepatitis Diagnosis and Treatment Market Growth, by Region 2021-2027

Global Autoimmune Hepatitis Diagnosis and Treatment Market region

Asia-Pacific is projected to grow significantly in the global Autoimmune Hepatitis Diagnosis and Treatment market

Geographically, Asia-Pacific is estimated to have considerable CAGR in the global Autoimmune Hepatitis Diagnosis and Treatment market during the forecast period. The growth is attributed to the increasing percentage of the aged population diagnosing liver-related diseases is the major factor driving the growth of the market. Further, high R&D investments and the presence of key players are also some of the factors expected to drive the growth of the region's market for autoimmune hepatitis diagnosis and treatment. However, stringent regulations of the FDA and MHRA for approval of drugs, high cost associated with the development of new drugs, high cost involved in the treatment of autoimmune hepatitis diagnosis will be restraining the growth of the Asia-Pacific autoimmune hepatitis diagnosis and treatment market.

Market Players Outlook

The key players of the autoimmune hepatitis diagnosis and treatment market include Gilead Lifesciences, Inc., Merck & Co., Inc., Bio-Rad Laboratories, Inc. Novartis International AG, Abbott Laboratories, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, Pfizer Inc announced a strategic collaboration agreement Vivet Therapeutics. Under this agreement, Pfizer will supply clinical supplies for a Phase 1/2 clinical trial by assessing Vivet's proprietary investigational gene therapy, VTX-801, for the potential cure of Wilson disease, a rare and potentially fatal liver disorder. This collaboration with Vivet highlights the importance of Pfizer's strategic investments in end-to-end gene therapy research and supply to support the timely delivery of these critical new therapies for patients.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Autoimmune Hepatitis Diagnosis and Treatment market

Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Autoimmune Hepatitis Diagnosis and Treatment Industry
  • Recovery Scenario of Global Autoimmune Hepatitis Diagnosis and Treatment Industry
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis
    • 5.1.1. Blood Test
    • 5.1.2. Imaging Test
    • 5.1.3. Liver Biopsy
  • 5.2. Global Autoimmune Hepatitis Diagnosis and Treatment market by Treatment
    • 5.2.1. Medication
    • 5.2.2. Corticosteroids
    • 5.2.3. Immune System Suppressors
    • 5.2.4. Liver Transplant
  • 5.3. Global Autoimmune Hepatitis Diagnosis and Treatment market by Type
    • 5.3.1. Type-I
    • 5.3.2. Type-II
    • 5.3.3. Variant AIH
  • 5.4. Global Autoimmune Hepatitis Diagnosis and Treatment market by End-User
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostic Centre
    • 5.4.3. Research Institutions

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

1. Abbott Laboratories,

2. AbbVie, Inc.

3. Arihantanam Life Care Pvt Ltd.

4. AstraZeneca PLC

5. Bayer AG

6. Biocon, Ltd.

7. Bio-Rad Laboratories, Inc.

8. Bristol-Myers Squibb Co.

9. Cipla, Ltd.

10. GlaxoSmithKline PLC

11. Gilead Lifesciences, Inc.

12. Johnson & Johnson Services, Inc.

13. Inova Diagnostics, Inc.

14. Merck & Co., Inc.

15. Novartis International AG

16. Organovo Holdings, Inc.

17. Pfizer, Inc.

18. Upcyte Technologies GmbH